Scientific article

Letter

English

Efficacy and safety of Daratumumab for the treatment of ABO-incompatible pure red cell aplasia after allogenic HSCT : report from SFGM-TC

ContributorsLongval, Thomas

; Leprêtre, Anne-Claire; Ravinet, Aurélie; Fayard, Amandine; Forcade, Edouard

; Coman, Tereza; Redjoul, Rabah; Berceanu, Ana; Buchbinder, Nimrod; Berlie, Guillaume; Mappoura, Maria

; Giannotti, Federica; Chevillon, Florian; Robin, Marie

; Peffault de Latour, Régis; Sicre de Fontbrune, Flore

; Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)

Published inBone marrow transplantation, vol. 59, no. 6, p. 893-895

Publication date2024-06

First online date2024-03-09

Keywords

Humans
Hematopoietic Stem Cell Transplantation / adverse effects
Hematopoietic Stem Cell Transplantation / methods
Red-Cell Aplasia, Pure / drug therapy
Red-Cell Aplasia, Pure / etiology
Red-Cell Aplasia, Pure / therapy
Antibodies, Monoclonal / therapeutic use
ABO Blood-Group System
Male
Female
Middle Aged
Adult
Allografts
Blood Group Incompatibility
Transplantation, Homologous / methods

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de médecine

Research groups

Leucémie et transplantation allogénique de cellules souches hématopoïétiques (982)

Citation (ISO format)

LONGVAL, Thomas et al. Efficacy and safety of Daratumumab for the treatment of ABO-incompatible pure red cell aplasia after allogenic HSCT : report from SFGM-TC. In: Bone marrow transplantation, 2024, vol. 59, n° 6, p. 893–895. doi: 10.1038/s41409-024-02202-9

Article (Published version)

Identifiers

PID : unige:179623
DOI : 10.1038/s41409-024-02202-9
PMID : 38461290

Additional URL for this publicationhttps://www.nature.com/articles/s41409-024-02202-9

Journal ISSN0268-3369

74views

0downloads

Creation13/08/2024 09:05:27

First validation04/09/2024 09:14:03

Update04/09/2024 09:14:03

Status update04/09/2024 09:14:03

Last indexation01/11/2024 10:54:10